Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan
Journal
Journal of the Formosan Medical Association
Journal Volume
119
Journal Issue
12
Pages
1871-1875
Date Issued
2020
Abstract
Despite the excellent antiviral effects of direct acting antivirals (DAAs) for hepatitis C virus (HCV) infection with subsequent decrease of morbidity and mortality, a small proportion (5%) of the treated patients do not respond to first-line DAAs and have persistent viremia. Rescue therapy for patients with DAA failures is thus mandatory from both clinical and public health perspectives. Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX), a fixed-dose pangenotypic rescue agent, has been approved by the Food and Drug Administration (FDA) and European Medical Agency (EMA) for retreating HCV patients who fail prior DAA therapies. However, this agent has not been licensed by health authorities of Taiwan. Herein we reported two cases who successfully cleared HCV by using SOF/VEL/VOX plus ribavirin (RBV) after virologic failures to first-line pangenotypic SOF/VEL. Furthermore, we discussed the current unmet medical needs and clinical implications of SOF/VEL/VOX on the perspectives of HCV elimination in Taiwan. ? 2020 Formosan Medical Association
SDGs
Other Subjects
ribavirin; robatrol; sofosbuvir plus velpatasvir plus voxilaprevir; virus RNA; 2 amino 2 methylpropionic acid; antivirus agent; carbamic acid derivative; cyclopropane derivative; fused heterocyclic rings; leucine; macrocyclic lactam; proline; quinoxaline derivative; ribavirin; sofosbuvir; sulfonamide; velpatasvir; voxilaprevir; adult; antiviral activity; Article; case report; chronic hepatitis C; clinical article; Hepatitis B virus; human; Human immunodeficiency virus infection; male; medical history; middle aged; mixed infection; Taiwan; treatment duration; viral clearance; chronic hepatitis C; drug combination; genotype; sustained virologic response; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan
Publisher
Elsevier B.V.
Type
journal article